Lindsay Hample

Boston Scientific Interventional Oncology & Embolization Global Marketing & Strategy. Wife and mom of 3. My views are my own.

[Lindsay Hample @HampleLindsay]

Huge day for our team! Thank you to @thefibroidlady and the rest of our advisor team for being with us from the beginning and developing a coil platform intentionally designed for IR applications. Excited for the many patients who will benefit from this technology. #EMBOLDcoils

[Peter Pattison @bsc_io_e]

An exciting milestone was met this week thanks to @thefibroidlady who performed the 1st in human #EMBOLDcoils case – pt suffered from multiple pulmonary AVMs that were successfully occluded. Huge TY Dr. Caridi for your partnership along the way. #iRad https://t.co/2vYWt4xL07

[Kirema Garcia-Reyes, MD @kiremagarciamd]

Live @MountSinaiIR

First-in-the-world #AnyDayDosing ✅

1st dose complete—rad seg for HCC 4 days post-calibration (Monday) using #TheraSphere Any Day Dosing.

Proud to help push this forward. Expanding what’s possible for our patients.

#TheraSphere360 #Y90 #HCC

[Lindsay Hample @HampleLindsay]

Excited to welcome the @InteraOncology team to Boston Scientific!

[Boston Scientific @bostonsci]

We’ve closed the acquisition of @InteraOncology, provider of the Intera 3000 Hepatic Artery Infusion Pump and floxuridine. We look forward to adding this technology to our portfolio and advancing treatment for patients with liver cancer.

[Riad Salem @riadsalemIR]

@SIRspecialists Abstract of the year! First in man Y90 for recurrent GBM. Outstanding outcomes. Precision+imaging confirmation. Incredible MultiD collaboration. Thanks Roger Stupp! Onward! @bsc_io @cirsesociety @ASTRO_org @ESTRO_RT @ASCO @NorthwesternMed @NURadiology @SamMouli

[Peter Pattison @bsc_io_e]

#SIR25NASH is off to a great start!

[Peter Pattison @bsc_io_e]

Another highlight from #SIOVegas. Excited to be a part of this important trial treating patients with painful bone metastases.

#ablation #cryoablation #VisualICE #ICEfx

[Peter Pattison @bsc_io_e]

Thanks for a great few days at #SIOVegas, here's to more collaboration and innovation in 2025 & beyond!

#irad #interventionalradiology #interventionaloncology @SphereVegas

[Peter Pattison @bsc_io_e]

Thank you, Interventional Radiologists! We are so grateful for your leadership and partnership. #SIOVegas #iRad @SphereVegas @SIO_Central

[Lindsay Hample @HampleLindsay]

When you have the best team and best physician partners 😊 #therasphere #irad

[Osman Ahmed @TheRealDoctorOs]

This might be the single coolest thing / publicity I’ve ever seen for #irad ! @SIO_Central @bsc_io @Jkhileman

[Peter Pattison @bsc_io_e]

Extremely pleased to share that we have completed initial enrollment for the #FRONTIERstudy. Thank you to the @NorthwesternIR team and to all of the FRONTIER sites for your dedication to this trial and to advancing treatment of recurrent GBM. Stay tuned for more #Y90 and #TheraSphereGBM updates. Sign up for updates here: https://t.co/FOQ2wPck1c

[Riad Salem @riadsalemIR]

Y90 RADSEG now #1 bridging treatment in US ahead of TACE, ablation and EBRT @JVIRmedia @allisonkwong @DanSzeMDPhD @SIRspecialists @cirsesociety @ASTSChimera @AASLDtweets @EASLnews @_ILTS_ @AST_info @ASTRO_org @ACRORadOnc @NorthwesternIR @NorthwesternMed
https://t.co/qV328UNiXN

[Peter Pattison @bsc_io_e]

William Harris, MD covers the HCRN GI15-225 pilot study, which investigated the safety and efficacy of combining pembrolizumab with TheraSphere Y-90 radioembolization for non-metastatic, poor prognosis hepatocellular carcinoma (HCC). Watch the OncLive read out here: https://t.co/QcYJmWnMYx

#Therasphere #Y90 #HCC #Immunotherapy

Safety: https://t.co/IDLT70XUZz

[Peter Pattison @bsc_io_e]

Patients are at the center of all the hard work and advancement being done to treat #HCC. In an effort to better support clinicians, we have developed additional patient education resources for #TheraSphere. View them here: https://t.co/aj13agGqqZ

#LiverCancerAwarenessMonth

[Peter Pattison @bsc_io_e]

NEW #TheraSphere Data! Single-center data builds on previously published radiation segmentectomy studies #LEGACYstudy and #RASERstudy to demonstrate consistent outcomes with late first week/early second week dosing. See the full publication: https://t.co/YM5UXJRjOy

Safety: https://t.co/IDLT70YsP7

[Peter Pattison @bsc_io_e]

Great to have so many members of the BSC team present at the @naaap Leadership Convention last week. This important event helped move the needle in breaking the silence and addressing health equity in the AAPI community. TY @freez_IR for your hard work and dedication.

[Lindsay Hample @HampleLindsay]

@YixuanYuki @freez_IR @naaap What an outstanding group of panelists! Should be an excellent session.

[Lindsay Hample @HampleLindsay]

One of the best attributes of BSC is our commitment to diversity and inclusion. Sponsorship of the NAAAP is another example. An exceptional group of panelists with important insights to share. Looking forward to hearing from Dr. Alda Tam @freez_IR, Dr. Ken Stein, and Yuki!

[Cat Jennings @bsc_vascular]

Same care everywhere #MIIP’s #IRad

[Road2IR @Road2IR]

Good times at @bostonsci Global Impact Summit in Chicago with friends from near and far! #LetsGo

🇺🇸 🇹🇿 🇺🇬 🇳🇬 🇨🇦 🇩🇪

@ericmbuguje @eva_nabawanuka @fabianmaxlg @farouk_dako @frankminja @angiowoman @VRamaMD @AlanMatsumotoMD @masch101 @Interventional2

[Peter Pattison @bsc_io_e]

Thrilled to introduce the #OCCLUDEregistry, a multi-center registry assessing the effectiveness & safety outcomes of #Obsidio #ConformableEmbolic. This would not be possible without lead PI Rahul Patel, MD @RSP516 @MountSinaiIR, thank you for all of the hard work!

[Peter Pattison @bsc_io_e]

New JVIR #Obsidio #ConformableEmbolic Publication! This single-center retrospective study evaluated outcomes following embolization using Obsidio. Read the full publication here: https://t.co/dbekW2Pnpv @JVIRmedia https://t.co/D9KRhh9KUg